

Ilium Butorgesic Injection Troy Laboratories Pty Ltd

Chemwatch: 5398-48 Version No: 3.1

Safety Data Sheet according to Work Health and Safety Regulations (Hazardous Chemicals) 2023 and ADG requirements

Chemwatch Hazard Alert Code: 2

Issue Date: 20/08/2021 Print Date: 31/03/2025 L.GHS.AUS.EN.E

SECTION 1 Identification of the substance / mixture and of the company / undertaking

| Product Identifier | |
|-------------------------------|----------------------------|
| Product name | Ilium Butorgesic Injection |
| Chemical Name | Not Applicable |
| Synonyms | APVMA number: 63462 |
| Chemical formula | Not Applicable |
| Other means of identification | Not Available |

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses Analgesic and sedative for use in horses, dogs and cats. To be used as directed on product label.

Details of the manufacturer or supplier of the safety data sheet

| Registered company name | Troy Laboratories Pty Ltd | |
|-------------------------|---|--|
| Address | Glendenning Road Glendenning NSW 2761 Australia | |
| Telephone | 02 8808 3600 | |
| Fax | 02 9677 9300 | |
| Website | www.Troylab.com.au | |
| Email | admin@troylab.com.au | |

Emergency telephone number

| Association / Organisation | Ixom Emergency Response Service | |
|-------------------------------------|---------------------------------|--|
| Emergency telephone number(s) | 1800 033 111 (24 hours) | |
| Other emergency telephone number(s) | Not Available | |

SECTION 2 Hazards identification

Classification of the substance or mixture

| Poisons Schedule | S8 |
|-------------------------------|--|
| Classification ^[1] | Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2A |
| Legend: | 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI |

Label elements

Hazard pictogram(s)



Signal word

Warning

Chemwatch: **5398-48**Version No: **3.1**

Ilium Butorgesic Injection

Issue Date: 20/08/2021 Print Date: 31/03/2025

Hazard statement(s)

| H315 | Causes skin irritation. |
|------|--------------------------------|
| H319 | Causes serious eye irritation. |

Precautionary statement(s) Prevention

| P280 | Wear protective gloves, protective clothing, eye protection and face protection. | |
|------|--|--|
| P264 | Wash all exposed external body areas thoroughly after handling. | |

Precautionary statement(s) Response

| P305+P351+P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. | |
|----------------|--|--|
| P337+P313 | If eye irritation persists: Get medical advice/attention. | |
| P302+P352 | IF ON SKIN: Wash with plenty of water. | |
| P332+P313 | If skin irritation occurs: Get medical advice/attention. | |
| P362+P364 | Take off contaminated clothing and wash it before reuse. | |

Precautionary statement(s) Storage

Not Applicable

Precautionary statement(s) Disposal

Not Applicable

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

| CAS No | %[weight] | Name |
|---------------|---|-----------------------------|
| 58786-99-5 | 1-10 | <u>butorphanol tartrate</u> |
| 7647-14-5 | <1 | sodium chloride |
| 5949-29-1 | <1 | citric acid, monohydrate |
| Not Available | balance Ingredients determined not to be hazardous | |
| Legend: | 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L * EU IOELVs available | |

SECTION 4 First aid measures

Description of first aid measures

| Eye Contact | If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel. |
|--------------|---|
| Skin Contact | If skin contact occurs: ► Immediately remove all contaminated clothing, including footwear. ► Flush skin and hair with running water (and soap if available). ► Seek medical attention in event of irritation. |
| Inhalation | If fumes, aerosols or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary. |
| Ingestion | For advice, contact a Poisons Information Centre or a doctor at once. Urgent hospital treatment is likely to be needed. If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Transport to hospital or doctor without delay. |

 Chemwatch: 5398-48
 Page 3 of 12
 Issue Date: 20/08/2021

 Version No: 3.1
 Print Date: 31/03/2025

Ilium Butorgesic Injection

Treat symptomatically.

As in all cases of suspected poisoning, follow the ABCDEs of emergency medicine (airway, breathing, circulation, disability, exposure), then the ABCDEs of toxicology (antidotes, basics, change absorption, change distribution, change elimination).

For poisons (where specific treatment regime is absent):

BASIC TREATMENT

- Establish a patent airway with suction where necessary.
- Watch for signs of respiratory insufficiency and assist ventilation as necessary.
- Administer oxygen by non-rebreather mask at 10 to 15 L/min.
- Monitor and treat, where necessary, for pulmonary oedema.
- Monitor and treat, where necessary, for shock.
- Anticipate seizures.
- DO NOT use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.

ADVANCED TREATMENT

• Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.

- Positive-pressure ventilation using a bag-valve mask might be of use.
- Monitor and treat, where necessary, for arrhythmias.
- Fastart an IV D5W TKO. If signs of hypovolaemia are present use lactated Ringers solution. Fluid overload might create complications.
- Drug therapy should be considered for pulmonary oedema.
- Hypotension with signs of hypovolaemia requires the cautious administration of fluids. Fluid overload might create complications.
- Treat seizures with diazepam.
- Proparacaine hydrochloride should be used to assist eye irrigation.

BRONSTEIN, A.C. and CURRANCE, P.L.

EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994

SECTION 5 Firefighting measures

Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances.

In such an event consider:

- ▶ foam
- dry chemical powder.
- carbon dioxide.

Special hazards arising from the substrate or mixture

Fire Incompatibility None known.

Advice for firefighters

| Alert Fire Brigade and tell them location and nature of hazard. | |
|--|----------|
| Wear breathing apparatus plus protective gloves in the event of a fire | <u>.</u> |

- Prevent, by any means available, spillage from entering drains or water courses.
- Use fire fighting procedures suitable for surrounding area.
- ▶ DO NOT approach containers suspected to be hot.
- ▶ Cool fire exposed containers with water spray from a protected location.
- If safe to do so, remove containers from path of fire.
- Equipment should be thoroughly decontaminated after use.

▶ The material is not readily combustible under normal conditions.

- ▶ However, it will break down under fire conditions and the organic component may burn.
- Not considered to be a significant fire risk.
 Heat may cause expansion or decomposition with violent rupture of containers.
- ▶ Decomposes on heating and may produce toxic fumes of carbon monoxide (CO).
- Fire/Explosion Hazard May emit acrid smoke.

Decomposes on heating and produces toxic fumes of:

carbon dioxide (CO2)

nitrogen oxides (NOx)

other pyrolysis products typical of burning organic material.

May emit corrosive fumes.

HAZCHEM

Fire Fighting

Not Applicable

SECTION 6 Accidental release measures

Chemwatch: 5398-48

Ilium Butorgesic Injection

Page 4 of 12 Issue Date: 20/08/2021 Print Date: 31/03/2025

Personal precautions, protective equipment and emergency procedures

See section 8

Version No: 3.1

Environmental precautions

See section 12

Methods and material for containment and cleaning up

| Minor Spills | Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment. Contain and absorb spill with sand, earth, inert material or vermiculite. Wipe up. Place in a suitable, labelled container for waste disposal. |
|--------------|--|
| Major Spills | Moderate hazard. Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water course. Stop leak if safe to do so. Contain spill with sand, earth or vermiculite. Collect recoverable product into labelled containers for recycling. Neutralise/decontaminate residue (see Section 13 for specific agent). Collect solid residues and seal in labelled drums for disposal. Wash area and prevent runoff into drains. After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. If contamination of drains or waterways occurs, advise emergency services. |

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Safe handling

Precautions for safe handling

- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.
- Use in a well-ventilated area.
- Prevent concentration in hollows and sumps.
- DO NOT enter confined spaces until atmosphere has been checked.
- ▶ DO NOT allow material to contact humans, exposed food or food utensils.
- Avoid contact with incompatible materials.
 - ▶ When handling, **DO NOT** eat, drink or smoke
 - Keep containers securely sealed when not in use.
 - Avoid physical damage to containers.
 - Always wash hands with soap and water after handling.
 - ▶ Work clothes should be laundered separately. Launder contaminated clothing before re-use.
 - Use good occupational work practice.
 - ▶ Observe manufacturer's storage and handling recommendations contained within this SDS.
 - Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.

Other information

- NOTE: Special security requirements may be mandated under Federal/State Regulation(s).
- Store in original containers. ▶ Store in vault fitted with warning devices or detectors recommended by various Federal/State authorities.
- Store in vault used only for the purpose of storage of drugs of addiction.
- Vault must be locked at all times except when the materials stored therein are required. • Keep storage area free from debris, wastes and combustibles.
- ▶ Keep dry.
- ▶ Keep containers securely sealed.
- Protect containers against physical damage.
- Check regularly for spills and leaks.

Conditions for safe storage, including any incompatibilities

Suitable container

- Packaging as recommended by manufacturer.
- Check that containers are clearly labelled.
- Tamper-proof containers.
 - ▶ Polyethylene or polypropylene containers.
 - Metal drum with sealed plastic liner.
 - ▶ Glass container is suitable for laboratory quantities

Storage incompatibility

- Avoid reaction with oxidising agents
- Avoid strong acids, bases.

Chemwatch: 5398-48

Ilium Butorgesic Injection

Issue Date: **20/08/2021**Print Date: **31/03/2025**

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Not Available

| Ingredient | Original IDLH | Revised IDLH |
|--------------------------|---------------|---------------|
| butorphanol tartrate | Not Available | Not Available |
| sodium chloride | Not Available | Not Available |
| citric acid, monohydrate | Not Available | Not Available |

MATERIAL DATA

Exposure controls

Enclosed local exhaust ventilation is required at points of dust, fume or vapour generation.

HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours. Barrier protection or laminar flow cabinets should be considered for laboratory scale handling.

A fume hood or vented balance enclosure is recommended for weighing/ transferring quantities exceeding 500 mg. When handling quantities up to 500 gram in either a standard laboratory with general dilution ventilation (e.g. 6-12 air changes per hour) is preferred. Quantities up to 1 kilogram may require a designated laboratory using fume hood, biological safety cabinet, or approved vented enclosures. Quantities exceeding 1 kilogram should be handled in a designated laboratory or containment laboratory using appropriate barrier/ containment technology.

Manufacturing and pilot plant operations require barrier/ containment and direct coupling technologies.

Barrier/ containment technology and direct coupling (totally enclosed processes that create a barrier between the equipment and the room) typically use double or split butterfly valves and hybrid unidirectional airflow/ local exhaust ventilation solutions (e.g. powder containment booths). Glove bags, isolator glove box systems are optional. HEPA filtration of exhaust from dry product handling areas is required.

Fume-hoods and other open-face containment devices are acceptable when face velocities of at least 1 m/s (200 feet/minute) are achieved. Partitions, barriers, and other partial containment technologies are required to prevent migration of the material to uncontrolled areas. For non-routine emergencies maximum local and general exhaust are necessary. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

| Type of Contaminant: | Air Speed: |
|---|----------------------------------|
| solvent, vapours, etc. evaporating from tank (in still air) | 0.25-0.5 m/s (50- 100 f/min.) |
| aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers (released at low velocity into zone of active generation) | 0.5-1 m/s (100-200 f/min.) |
| direct spray, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion) | 1-2.5 m/s (200-500 f/min.) |

Appropriate engineering controls

Within each range the appropriate value depends on:

| Lower end of the range | Upper end of the range |
|--|----------------------------------|
| 1: Room air currents minimal or favourable to capture | 1: Disturbing room air currents |
| 2: Contaminants of low toxicity or of nuisance value only. | 2: Contaminants of high toxicity |
| 3: Intermittent, low production. | 3: High production, heavy use |
| 4: Large hood or large air mass in motion | 4: Small hood-local control only |

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2.5 m/s (200-500 f/min.) for extraction of gases discharged 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated: Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated.

The following protective devices are recommended where exposures exceed the recommended exposure control guidelines by factors of:

10; high efficiency particulate (HEPA) filters or cartridges

10-25; loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator.

25-50; a full face-piece negative pressure respirator with HEPA filters

50-100; tight-fitting, full face-piece HEPA PAPR

100-1000; a hood-shroud HEPA PAPR or full face-piece supplied air respirator operated in pressure demand or other positive pressure mode.

Chemwatch: 5398-48 Page 6 of 12

Ilium Butorgesic Injection

Issue Date: 20/08/2021 Print Date: 31/03/2025

Individual protection measures, such as personal protective equipment

Version No: 3.1











When handling very small quantities of the material eye protection may not be required.

For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

- Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent]
- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes.

Eye and face protection

▶ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

Skin protection

See Hand protection below

Hands/feet protection

- ▶ Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference
- Double gloving should be considered.
- PVC gloves.
- ▶ Change gloves frequently and when contaminated, punctured or torn.
- Wash hands immediately after removing gloves.
- ▶ Protective shoe covers. [AS/NZS 2210]
- Head covering.

Body protection

Other protection

See Other protection below

▶ For quantities up to 500 grams a laboratory coat may be suitable.

- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable
- shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- ▶ For Emergencies: Vinyl suit

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the computer-generated selection:

Ilium Butorgesic Injection

| Material | СРІ |
|------------------|-----|
| BUTYL | С |
| NATURAL RUBBER | С |
| NATURAL+NEOPRENE | С |
| NEOPRENE | С |
| NITRILE | С |
| PVA | С |
| PVC | С |
| VITON | С |

- * CPI Chemwatch Performance Index
- A: Best Selection
- B: Satisfactory; may degrade after 4 hours continuous immersion
- C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove. a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis. factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Ansell Glove Selection

Glove — In order of recommendation

Respiratory protection

Type A Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

| Required minimum protection factor | Maximum gas/vapour concentration present in air p.p.m. (by volume) | Half-face Respirator | Full-Face Respirator |
|---|--|-------------------------|-------------------------|
| up to 10 | 1000 | A-AUS / Class1 | - |
| up to 50 | 1000 | - | A-AUS / Class 1 |
| up to 50 | 5000 | Airline * | - |
| up to 100 | 5000 | - | A-2 |
| up to 100 | 10000 | - | A-3 |
| 100+ | | | Airline** |

- * Continuous Flow ** Continuous-flow or positive pressure demand A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)
- ▶ Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too

Ilium Butorgesic Injection

Issue Date: 20/08/2021 Print Date: 31/03/2025

| AlphaTec® 15-554 |
|--------------------------|
| AlphaTec® Solvex® 37-185 |
| AlphaTec® 38-612 |
| AlphaTec® 58-008 |
| AlphaTec® 58-530B |
| AlphaTec® 58-530W |
| AlphaTec® 58-735 |
| AlphaTec® 79-700 |
| AlphaTec® Solvex® 37-675 |
| MICROFLEX® 63-864 |

only restricted use of cartridge respirators is considered appropriate. ▶ Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the

high, or that the mask is not properly fitted. Because of these limitations,

humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

The suggested gloves for use should be confirmed with the glove supplier.

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

| Appearance | Clear colourless liquid; mixes with water. | | |
|---|--|---|----------------|
| | | | |
| Physical state | Liquid | Relative density (Water = 1) | 3.5-5 |
| Odour | Not Available | Partition coefficient n- octanol / water | Not Available |
| Odour threshold | Not Available | Auto-ignition temperature (°C) | Not Applicable |
| pH (as supplied) | 1.014 | Decomposition temperature (°C) | Not Available |
| Melting point / freezing point (°C) | Not Available | Viscosity (cSt) | Not Available |
| Initial boiling point and boiling range (°C) | Not Available | Molecular weight (g/mol) | Not Applicable |
| Flash point (°C) | Not Applicable | Taste | Not Available |
| Evaporation rate | Not Available | Explosive properties | Not Available |
| Flammability | Not Applicable | Oxidising properties | Not Available |
| Upper Explosive Limit (%) | Not Applicable | Surface Tension (dyn/cm or mN/m) | Not Available |
| Lower Explosive Limit (%) | Not Applicable | Volatile Component (%vol) | Not Available |
| Vapour pressure (kPa) | Not Available | Gas group | Not Available |
| Solubility in water | Miscible | pH as a solution (1%) | Not Available |
| Vapour density (Air = 1) | Not Available | VOC g/L | Not Available |
| Heat of Combustion (kJ/g) | Not Available | Ignition Distance (cm) | Not Available |
| Flame Height (cm) | Not Available | Flame Duration (s) | Not Available |
| Enclosed Space Ignition Time Equivalent (s/m3) | Not Available | Enclosed Space Ignition Deflagration Density (g/m3) | Not Available |

SECTION 10 Stability and reactivity

| Reactivity | See section 7 |
|------------------------------------|--|
| Chemical stability | Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur. |
| Possibility of hazardous reactions | See section 7 |
| Conditions to avoid | See section 7 |
| Incompatible materials | See section 7 |
| Hazardous decomposition products | See section 5 |

SECTION 11 Toxicological information

Page 8 of 12

Ilium Butorgesic Injection

Based on available data, the classification criteria are not met.

There is sufficient evidence to classify this material as skin corrosive or irritating.

Issue Date: 20/08/2021 Print Date: 31/03/2025

Information on toxicological effects a) Acute Toxicity

c) Serious Eye

b) Skin Irritation/Corrosion

| c) Serious Eye Damage/Irritation | There is sufficient evidence to classify this material as eye damaging or irritating | | |
|--|--|--|--|
| d) Respiratory or Skin sensitisation | Based on available data, the classification criteria are not met. | | |
| e) Mutagenicity | Based on available data, the classification criteria are not met. | | |
| f) Carcinogenicity | Based on available data, the classification criteria are not met. | | |
| g) Reproductivity | Based on available data, the classification criteria are | not met. | |
| h) STOT - Single Exposure | Based on available data, the classification criteria are | not met. | |
| i) STOT - Repeated Exposure | Based on available data, the classification criteria are not met. | | |
| j) Aspiration Hazard | Based on available data, the classification criteria are | not met. | |
| Inhaled | The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified by EC Directives using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting. Not normally a hazard due to non-volatile nature of product | | |
| Ingestion | The material has NOT been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern. | | |
| Skin Contact | Evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. The material may accentuate any pre-existing dermatitis condition Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected. | | |
| | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with | |
| Еуе | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of th Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which a experimental animals. Repeated or prolonged eye contact may cause inflaments. | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with | |
| Eye | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of th Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which a experimental animals. Repeated or prolonged eye contact may cause inflamiconjunctiva (conjunctivitis); temporary impairment of v | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. the material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. | |
| • | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of th Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which a experimental animals. Repeated or prolonged eye contact may cause inflamiconjunctiva (conjunctivitis); temporary impairment of v Long-term exposure to the product is not thought to prusing animal models); nevertheless exposure by all ro | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives outes should be minimised as a matter of course. | |
| • | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume temporary exposure to the product is not thought to provide using animal models); nevertheless exposure by all rootoxicity. | itis condition a, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. | |
| Chronic | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of th Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which a experimental animals. Repeated or prolonged eye contact may cause inflamiconjunctiva (conjunctivitis); temporary impairment of v Long-term exposure to the product is not thought to prusing animal models); nevertheless exposure by all ro | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives outes should be minimised as a matter of course. | |
| Chronic Ilium Butorgesic Injection | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume temporary exposure to the product is not thought to provide using animal models); nevertheless exposure by all rootoxicity. | itis condition a, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. | |
| Chronic | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to the product is not thought to provide using animal models); nevertheless exposure by all romain animal models. | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. the material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the vision and/or other transient eye damage/ulceration may occur. roduce chronic effects adverse to health (as classified by EC Directives outes should be minimised as a matter of course. IRRITATION Not Available | |
| Chronic Ilium Butorgesic Injection | The material may accentuate any pre-existing dermati Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of th Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which a experimental animals. Repeated or prolonged eye contact may cause inflamiconjunctiva (conjunctivitis); temporary impairment of v Long-term exposure to the product is not thought to prusing animal models); nevertheless exposure by all romatical to the product of the prod | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives buttes should be minimised as a matter of course. IRRITATION Not Available IRRITATION | |
| Chronic Ilium Butorgesic Injection | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which an experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to the product is not thought to provide using animal models); nevertheless exposure by all romain animal models. TOXICITY Not Available TOXICITY Oral (Dog) LD50; >50 mg/kg ^[2] | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. the material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. roduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Not Available IRRITATION Not Available IRRITATION | |
| Chronic Ilium Butorgesic Injection | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to product it is not thought to provide animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing to animal models. | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. Ithe material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Irroduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Reference of the product of the pro | |
| Chronic Ilium Butorgesic Injection | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to product it is not thought to prove using animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing animal models); TOXICITY Not Available TOXICITY Oral (Dog) LD50; >50 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: >10000 mg/kg ^[1] Inhalation (Rat) LC50: >10.5 mg/l4h ^[1] | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. the material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Eye (Rodent - rabbit): 100mg/24H - Moderate Eye (Rodent - rabbit): 10mg - Moderate | |
| Chronic Ilium Butorgesic Injection butorphanol tartrate | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to product it is not thought to provide animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing to animal models. | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Reye (Rodent - rabbit): 100mg/24H - Moderate Eye (Rodent - rabbit): 10mg - Moderate Eye: adverse effect observed (irritating)[1] | |
| Chronic Ilium Butorgesic Injection butorphanol tartrate | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to product it is not thought to prove using animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing animal models); TOXICITY Not Available TOXICITY Oral (Dog) LD50; >50 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: >10000 mg/kg ^[1] Inhalation (Rat) LC50: >10.5 mg/l4h ^[1] | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. the material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. roduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Eye (Rodent - rabbit): 100mg/24H - Moderate Eye (Rodent - rabbit): 10mg - Moderate Eye: adverse effect observed (irritating)[1] Skin (Rodent - rabbit): 500mg/24H - Mild | |
| Chronic Ilium Butorgesic Injection butorphanol tartrate | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to product it is not thought to prove using animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing animal models); TOXICITY Not Available TOXICITY Oral (Dog) LD50; >50 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: >10000 mg/kg ^[1] Inhalation (Rat) LC50: >10.5 mg/l4h ^[1] | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Reye (Rodent - rabbit): 100mg/24H - Moderate Eye (Rodent - rabbit): 10mg - Moderate Eye: adverse effect observed (irritating)[1] | |
| Chronic Ilium Butorgesic Injection butorphanol tartrate | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to product it is not thought to prove using animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing animal models); TOXICITY Not Available TOXICITY Oral (Dog) LD50; >50 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: >10000 mg/kg ^[1] Inhalation (Rat) LC50: >10.5 mg/l4h ^[1] | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. the material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. roduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Eye (Rodent - rabbit): 100mg/24H - Moderate Eye (Rodent - rabbit): 10mg - Moderate Eye: adverse effect observed (irritating)[1] Skin (Rodent - rabbit): 500mg/24H - Mild | |
| Chronic Ilium Butorgesic Injection butorphanol tartrate | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamiconjunctiva (conjunctivitis); temporary impairment of v. Long-term exposure to the product is not thought to provide animal models); nevertheless exposure by all rousing animal models); nevertheless exposure by all rousing (Dog) LD50; >50 mg/kg ^[2] TOXICITY Oral (Dog) LD50; >50 mg/kg ^[2] TOXICITY Dermal (rabbit) LD50: >10000 mg/kg ^[1] Inhalation (Rat) LC50: >10.5 mg/l4h ^[1] Oral (Rat) LD50: 3000 mg/kg ^[2] | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Eye (Rodent - rabbit): 100mg/24H - Moderate Eye (Rodent - rabbit): 10mg - Moderate Eye: adverse effect observed (irritating)[1] Skin (Rodent - rabbit): 500mg/24H - Mild Skin: no adverse effect observed (not irritating)[1] | |
| Chronic Ilium Butorgesic Injection butorphanol tartrate | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to the product is not thought to provide animal models); nevertheless exposure by all rousing | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Eye (Rodent - rabbit): 100mg/24H - Moderate Eye (Rodent - rabbit): 10mg - Moderate Eye: adverse effect observed (irritating)[1] Skin (Rodent - rabbit): 500mg/24H - Mild Skin: no adverse effect observed (not irritating)[1] IRRITATION | |
| Chronic Ilium Butorgesic Injection butorphanol tartrate sodium chloride | The material may accentuate any pre-existing dermatic Entry into the blood-stream through, for example, cuts harmful effects. Examine the skin prior to the use of the Evidence exists, or practical experience predicts, that and/or may produce significant ocular lesions which are experimental animals. Repeated or prolonged eye contact may cause inflamic conjunctiva (conjunctivitis); temporary impairment of volume to the product is not thought to provide animal models); nevertheless exposure by all rousing | itis condition s, abrasions, puncture wounds or lesions, may produce systemic injury with the material and ensure that any external damage is suitably protected. The material may cause eye irritation in a substantial number of individuals are present twenty-four hours or more after instillation into the eye(s) of mation characterised by temporary redness (similar to windburn) of the rision and/or other transient eye damage/ulceration may occur. Troduce chronic effects adverse to health (as classified by EC Directives butes should be minimised as a matter of course. IRRITATION Not Available IRRITATION Eye (Rodent - rabbit): 100mg/24H - Moderate Eye: (Rodent - rabbit): 10mg - Moderate Eye: adverse effect observed (irritating)[1] Skin (Rodent - rabbit): 500mg/24H - Mild Skin: no adverse effect observed (not irritating)[1] IRRITATION Eye (Rodent - rabbit): 5mg/30S - Mild | |

Chemwatch: 5398-48 Page 9 of 12 Issue Date: 20/08/2021 Version No: 3.1 Print Date: 31/03/2025

Ilium Butorgesic Injection

Legend: 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

| BUTORPHANOL TARTRATE | Substance has been investigated as a reproductive effector in rodents. WARNING: Abuse can lead to habituation. Subject to Federal and State Regulations. Narcotic Substance, Schedule I (UN). | | |
|--|---|--------------------------|---|
| SODIUM CHLORIDE | The material may produce moderate eye irritation leading to inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis. The material may cause skin irritation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the production of vesicles, scaling and thickening of the skin. | | |
| CITRIC ACID, MONOHYDRATE | The material may be irritating to the eye, with prolonged contact causing inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis. | | |
| SODIUM CHLORIDE & CITRIC ACID, MONOHYDRATE | Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial byperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without | | |
| Acute Toxicity | × | Carcinogenicity | × |
| Skin Irritation/Corrosion | ~ | Reproductivity | × |
| Serious Eye Damage/Irritation | ~ | STOT - Single Exposure | × |
| Respiratory or Skin sensitisation | × | STOT - Repeated Exposure | × |

Legend: 🗶 – Data either not available or does not fill the criteria for classification Data available to make classification

×

Aspiration Hazard

SECTION 12 Ecological information

Mutagenicity

×

Toxicity

| | Endpoint | Test Duration (hr) | Species | Value | Source |
|----------------------------|------------------|--------------------|---|---------------------|------------------|
| llium Butorgesic Injection | Not Available | Not Available | Not Available | Not Available | Not Available |
| | Endpoint | Test Duration (hr) | Species | Value | Source |
| butorphanol tartrate | Not Available | Not Available | Not Available | Not Available | Not Available |
| | Endpoint | Test Duration (hr) | Species | Value | Source |
| | EC50 | 48h | Crustacea | 0.004- 0.006mg/L | 4 |
| | NOEC(ECx) | 6h | Fish | 0.001mg/L | 4 |
| sodium chloride | EC50 | 72h | Algae or other aquatic plants | 20.76- 36.17mg/L | 4 |
| | EC50 | 96h | Algae or other aquatic plants | 1110.36mg/L | 4 |
| | LC50 | 96h | Fish | 1000mg/L | 4 |
| -14-114 | Endpoint | Test Duration (hr) | Species | Value | Source |
| citric acid, monohydrate | EC10(ECx) | 24h | Algae or other aquatic plants | >1000mg/l | 4 |
| Legend: | 4. US EPA, Eco | , , | ECHA Registered Substances - Ecotoxicologia ata 5. ECETOC Aquatic Hazard Assessment Do | , | |

DO NOT discharge into sewer or waterways.

Persistence and degradability

| Ingredient | Persistence: Water/Soil | Persistence: Air |
|-----------------|-------------------------|------------------|
| sodium chloride | LOW | LOW |

Chemwatch: 5398-48 Page 10 of 12 Version No: 3.1

Ilium Butorgesic Injection

Issue Date: 20/08/2021 Print Date: 31/03/2025

| ingredient monohydrate | Persistence: Water/Soil | Рекъistence: Air |
|---------------------------|-------------------------|------------------|
| Bioaccumulative potential | | |

| Ingredient | | Bioaccumulation | |
|--------------------|--------|----------------------|--|
| sodium chloride | | LOW (LogKOW = 0.54) | |
| citric acid, monoh | ydrate | LOW (LogKOW = -1.64) | |

Mobility in soil

| Ingredient | Mobility |
|--------------------------|----------------------|
| sodium chloride | LOW (Log KOC = 14.3) |
| citric acid, monohydrate | LOW (Log KOC = 10) |

SECTION 13 Disposal considerations

Waste treatment methods

- ▶ DO NOT allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- Where in doubt contact the responsible authority.
- Recycle wherever possible.
- Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified.
- Product / Packaging disposal
- Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or incineration in a
- licensed apparatus (after admixture with suitable combustible material).
- ▶ Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.
- Containers may still present a chemical hazard/ danger when empty.
- Return to supplier for reuse/ recycling if possible.

Otherwise:

- If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
- ▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product.

SECTION 14 Transport information

Labels Required

| Marine Pollutant | NO |
|------------------|----------------|
| HAZCHEM | Not Applicable |

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.7. Maritime transport in bulk according to IMO instruments

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

| Product name | Group |
|--------------------------|---------------|
| butorphanol tartrate | Not Available |
| sodium chloride | Not Available |
| citric acid, monohydrate | Not Available |

14.7.3. Transport in bulk in accordance with the IGC Code

| Product name | Ship Type |
|--------------------------|---------------|
| butorphanol tartrate | Not Available |
| sodium chloride | Not Available |
| citric acid, monohydrate | Not Available |

Ilium Butorgesic Injection

Issue Date: 20/08/2021 Print Date: 31/03/2025

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

butorphanol tartrate is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 8

sodium chloride is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

citric acid, monohydrate is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australian Inventory of Industrial Chemicals (AIIC)

Additional Regulatory Information

Not Applicable

National Inventory Status

| National Inventory | Status | | |
|--|--|--|--|
| Australia - AIIC / Australia Non-Industrial Use | No (butorphanol tartrate) | | |
| Canada - DSL | No (butorphanol tartrate) | | |
| Canada - NDSL | No (butorphanol tartrate; sodium chloride; citric acid, monohydrate) | | |
| China - IECSC | No (butorphanol tartrate) | | |
| Europe - EINEC / ELINCS / NLP | Yes | | |
| Japan - ENCS | No (butorphanol tartrate) | | |
| Korea - KECI | No (butorphanol tartrate) | | |
| New Zealand - NZIoC | Yes | | |
| Philippines - PICCS | No (butorphanol tartrate) | | |
| USA - TSCA | TSCA Inventory 'Active' substance(s) (sodium chloride; citric acid, monohydrate); No (butorphanol tartrate) | | |
| Taiwan - TCSI | Yes | | |
| Mexico - INSQ | No (butorphanol tartrate) | | |
| Vietnam - NCI | Yes | | |
| Russia - FBEPH | No (butorphanol tartrate) | | |
| Legend: | Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration. | | |

SECTION 16 Other information

| Revision Date | 20/08/2021 |
|---------------|------------|
| Initial Date | 06/05/2020 |

SDS Version Summary

| Version | Date of Update | Sections Updated |
|---------|----------------|---|
| 3.1 | 20/08/2021 | Classification change due to full database hazard calculation/update. |

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

- ▶ PC TWA: Permissible Concentration-Time Weighted Average
- ▶ PC STEL: Permissible Concentration-Short Term Exposure Limit
- ▶ IARC: International Agency for Research on Cancer
- ▶ ACGIH: American Conference of Governmental Industrial Hygienists

Chemwatch: **5398-48** Page **12** of **12** Issue Date: **20/08/2021**

Version No: 3.1 Ilium Butorgesic Injection Print Date: 31/03/2025

- ▶ STEL: Short Term Exposure Limit
- ► TEEL: Temporary Emergency Exposure Limit。
- ▶ IDLH: Immediately Dangerous to Life or Health Concentrations
- ► ES: Exposure Standard
- ▶ OSF: Odour Safety Factor
- ▶ NOAEL: No Observed Adverse Effect Level
- ▶ LOAEL: Lowest Observed Adverse Effect Level
- ▶ TLV: Threshold Limit Value
- ▶ LOD: Limit Of Detection
- OTV: Odour Threshold Value
- ▶ BCF: BioConcentration Factors
- ▶ BEI: Biological Exposure Index
- ► DNEL: Derived No-Effect Level
- ▶ PNEC: Predicted no-effect concentration
- MARPOL: International Convention for the Prevention of Pollution from Ships
- ▶ IMSBC: International Maritime Solid Bulk Cargoes Code
- ▶ IGC: International Gas Carrier Code
- IBC: International Bulk Chemical Code
- ▶ AIIC: Australian Inventory of Industrial Chemicals
- ▶ DSL: Domestic Substances List
- ▶ NDSL: Non-Domestic Substances List
- ▶ IECSC: Inventory of Existing Chemical Substance in China
- ▶ EINECS: European INventory of Existing Commercial chemical Substances
- ▶ ELINCS: European List of Notified Chemical Substances
- ► NLP: No-Longer Polymers
- ▶ ENCS: Existing and New Chemical Substances Inventory
- ▶ KECI: Korea Existing Chemicals Inventory
- ▶ NZIoC: New Zealand Inventory of Chemicals
- ▶ PICCS: Philippine Inventory of Chemicals and Chemical Substances
- ► TSCA: Toxic Substances Control Act
- ▶ TCSI: Taiwan Chemical Substance Inventory
- ▶ INSQ: Inventario Nacional de Sustancias Químicas
- NCI: National Chemical Inventory
- ▶ FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.